Erythromycin: an alternative for the management of oral mucositis?

BACKGROUND: Oral mucositis (OM) is an important acute adverse effect of anticancer therapy. This condition presents high morbidity and may lead to the suspension of anticancer therapy. MATERIAL AND METHODS: We reviewed the literature on the pathobiology of OM and the properties of erythromycin (EM),...

Descripción completa

Detalles Bibliográficos
Autores principales: Teixeira, Dieni Silveira, Louzeiro, Gabriel Campos, de Figueiredo, Maria Antonia Zancanaro, Cherubini, Karen, Salum, Fernanda Gonçalves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medicina Oral S.L. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445611/
https://www.ncbi.nlm.nih.gov/pubmed/35717620
http://dx.doi.org/10.4317/medoral.25439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445611/
https://www.ncbi.nlm.nih.gov/pubmed/35717620
http://dx.doi.org/10.4317/medoral.25439

Ejemplares similares